Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 2 Terminated 6 enrolled Mirati Therapeutics Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine how effective azacitidine, MGCD0103, and the combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of age.

Timeline

Start: 2008-06
Primary completion: 2009-04
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azacitidine	Other / unclassified	75 mg/m2	Subcutaneous
Subject	Mocetinostat	Small molecule	90 mg	Oral

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Summary

Timeline

Drugs

Indications